Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan
An anemia drug helped most blood disorder patients avoid transfusions for years, with stable five-year survival matching disease expectations.
Post-marketing surveillance of darbepoetin alfa in 1834 Japanese MDS patients (2015-2024, median age 79) showed sustained hemoglobin improvement (7.6→>9.0 g/dL), transfusion independence in 40.9% of transfusion-dependent patients by year 4-5, and an AML transformation rate of 9.0%. Five-year overall survival stratified by IPSS risk confirms expected poor prognosis in intermediate/high-risk groups with no new safety signals identified.
What the study was
- Study design
- Post-marketing surveillance, prospective registry (UMIN000056049, 2015-2024)
- Population
- MDS patients treated with darbepoetin alfa in Japan (n=1834; median age 79 years; IPSS Low 39.3%, Int-1 45.1%)
- Sample size
- 1834
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International Journal of Hematology
Why it surfaced
Large real-world long-term dataset (n=1834, 5 years) for darbepoetin alfa in MDS — clinically relevant but confirmatory of known data. Industry-funded (Kyowa Kirin).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.